Unfortunately, this stock has never run purely on technicals and on biotech potential or else we would see a large premium like other biotechs at 100x earnings. There is a big push to gain credibility back with the institutional players and if that takes hold, we may slingshot past the technical valuations into biotech potential P/E's.

All I can say is that things look so amazing with a profit than they do with those years of losses and beatdown on the stock. Hope it goes up quick pushed by institutionals but they may take their time on the decision to really jump back in here, too.